A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
Condition: Influenza, Human Intervention: Biological: H5N1 antigen combined with MF59 adjuvant Sponsor: Seqirus Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2020 Category: Research Source Type: clinical trials